Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Teva Pharmaceutical Industries Ltd's rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx's lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx's decision secures easier access to customers for Lilly's Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen's Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva's Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp. "We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine," Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. "Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers," the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva's drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen's Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM's recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York were down nearly 1 percent at $19.69.

Output: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.

Input: Consider Input: The story doesn't address costs for any of the treatment options discussed. Is MBSR comparable to CBT? Does insurance cover either treatment option? The story tells readers what percentage of study participants who got MBSR treatment reported improvement in pain, as well as what percentage of MBSR participants "reported improvement in the activities they could do." It also offered the same numbers for participants who received CBT and for the control group, which received typical medical care for this condition. These detailsdeservea Satisfactory rating. But: The story notes: "The study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an 'adverse event,' most often an increase in pain due to yoga." It's good to see that included. Since the story is effectively comparing MBSR to CBT and conventional treatment, it would also have been worth noting "adverse events" for those groups in the study. According to the study, 10 percent of the CBT group also experienced "adverse events," and no adverse events were mentioned for the control group. Defining "adverse events" would also have been good, since it's not clear whether they mean momentary pain or a debilitating flare-up of long-term pain. According to the study, the painfor both MBSR and CBT groupswas "mostly temporary" and no "serious" adverse events were reported. Those things are worth mentioning. (It's also worth finding out what "mostly" and "serious" mean.) The story describes the study in detail, explicitly stating the study size and the absolute percentages in each arm that had benefit. It also acknowledged the study was randomized. We'll count this as sufficient for Satisfactory, keeping in mind the following: As explained in the summary above, the story doesn't make clear MBSR and CBT were used in addition to conventional medical treatment, rather than instead of medical treatment. The story didn't mention that the study excluded participants with what the study authors term "a specific diagnosis (eg, spinal stenosis)." In other words, the study did not address treatments for back pain caused by issues like a herniated disc or rheumatoid arthritis. Many readers have these conditions, and should be informed thatthese study results may not be applicable to their situation. Lastly, we would have welcomed a discussion of the high rates of success within thecontrol group. Forty-four percent in that group experienced a gain in functionality, for example. That seems pretty good! What do the researchers have to say about that? No disease mongering here. However, we did want to point out that the story "fear mongers" in a sense, by stating back pain is "one reason why more and more people are addicted to painkillers." The story insinuates that these other treatment methodsespecially meditationcould help with that. And maybe they could. But the study itself says "No overall differences in treatment effects were observed forself-reported use of medications for back pain." So why the mentionof painkiller addiction? Conflicts of interest don't appear to be an issue here, and the story includesstatements froman accompanying editorial in JAMA, which was written by experts unaffiliated with the research. This squeaks by as Satisfactory, though it should be noted that most of this material was available via news releases (see below). The story is effectively all about comparing alternatives, thoughagainit should have made clear that MBSR and CBT were used in conjunction with conventional medical treatment, and it left out discussion of other well-known non-medication treatment methods, such as exercise. It's not clear from the story whether MBSR is widely available, is available in mainly metropolitan areas, or is a relatively new field that is still uncommon. The story does quote from a separate editorial in JAMA that says health care systems "should provide access to affordable mind-body therapies,"implying that it's not widely available. Is this the case, or can it be easily accessed? Given the constraints of a brief news story, the piece does a nice job of articulating the differences between MBSR and CBT. It wouldhave been even more helpful for the story to mention previous studies on the impact of MBSR and CBT on low back pain, to help us understand how novel this new study is. There is little in the story that is not found in the two news releases issued on this study. (Those releases can be found here and here.)

Output: Mindful meditation may be the answer to relieving chronic back pain, study suggests

Input: Consider Input: Finally. Darnold was cleared by doctors Tuesday to play this week after he missed three games while recovering from mononucleosis. He had medical tests to determine if the swelling in his spleen a common symptom of the illness had dissipated enough for him to play again. The Jets announced in a Twitter post that Darnold would start Sunday at home against Dallas. It's some rare good news for the Jets, who are 0-4 their worst start since 2003 while dealing with several injuries to key players. And Darnold's illness is at the top of the list. The team was optimistic last week that Darnold would be able to play at Philadelphia, which was the initial goal for his return. Darnold took first-team snaps last Wednesday and Thursday, but an ultrasound and blood test last Thursday night revealed he was not yet able to be fully cleared. So Luke Falk on one day of full reps with the first-team offense started his second straight game for New York. The Jets lost 31-6 and Falk was sacked nine times and had two turnovers returned for touchdowns while New York struggled to get anything going on offense. That has been a common theme during Darnold's absence, with Adam Gase's offense ranking at or near the bottom of the league in several categories. New York has just 233 yards of total offense in its last two games combined. With Falk starting, the Jets had 105 against New England two weeks ago and 128 at Philadelphia. "It's probably more than just Sam getting out there," Gase said Monday. "We have a lot of other things to clean up. Sam is able to hide things sometimes for us, where if we make a mistake, he covers it up. I think we just need to do a better job as a group making sure that all 11 are on the same page." Darnold was diagnosed with mono on Sept. 11, three days after the season-opening loss to Buffalo. He acknowledged that he was beginning to experience symptoms leading into that game and was not 100% against the Bills, going 28 of 41 for 175 yards and a touchdown. He was sent home before practice three days later and received the diagnosis that night. Backup Trevor Siemian started in Week 2 against Cleveland, but he suffered season-ending ligament damage in his left ankle in the 23-3 loss. Falk, who had been on the practice squad until shortly before that game, came in and started the next two games for the Jets. Darnold was cleared for non-contact activity last Monday and appeared to be trending toward playing at Philadelphia until another medical test failed to bring positive results. But the quarterback was eager for the latest round of tests. "I'm excited to hear the news," Darnold said Monday during his weekly appearance on "The Michael Kay Show" on 98.7 ESPN Radio. "I have a feeling it's going to be good news. I thought maybe it would come last week, but I had to wait it out again. Hopefully, this week it's better news and I get to practice and get ready for a game on Sunday." Darnold is all clear now, and the Jets have their starting quarterback back on the field. "Let's get it Sammy," an excited running back Le'Veon Bell wrote on Twitter. Darnold said last week that when he was cleared to play, he would wear customized padding around his ribcage/spleen area to help protect him. That's something to watch as the Jets have allowed an NFL-leading 23 sacks. New York has two other key players returning this week in second-year tight end Chris Herndon, who was suspended by the NFL for the first four games for violating the league's substance-abuse policy, and outside linebacker Brandon Copeland, who also was banned four games for violating the NFL's policy on performance enhancers. The short-handed Jets are still waiting for linebackers C.J. Mosley (groin) and Jordan Jenkins (calf) to return, and starting left guard Kelechi Osemele is dealing with knee and shoulder injuries. Wide receiver Quincy Enunwa (neck) was lost for the season with a neck injury against Buffalo, further hindering the offense. "We have a lot of talent," defensive lineman Leonard Williams said Monday. "We're 0-4 right now, but the season isn't over and we still have a lot to fight for." ___ More AP NFL: https://apnews.com/NFL and https://twitter.com/AP_NFL
Output: Jets QB Sam Darnold cleared to play, will start vs. Cowboys.